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Abstract: To investigate the protective effects of protopanaxadiol-type ginsenoside (PDG) 
and its metabolite ginsenoside M1 (G-M1) on carbon tetrachloride (CCl4)-induced chronic 
liver injury in ICR mice, we carried out conversion of protopanaxadiol-type ginsenosides 
to ginsenoside M1 using snailase. The optimum time for the conversion was 24 h at a 
constant pH of 4.5 and an optimum temperature of 50 °C. The transformation products 
were identified by high-performance liquid chromatography and electrospray ion-mass 
spectrometry. Subsequently, most of PDG was decomposed and converted into G-M1 by 
24 h post-reaction. During the study on hepatoprotective in a mice model of chronic liver 
injury, PDG or G-M1 supplement significantly ameliorated the CCl4-induced liver lesions, 
lowered the serum levels of select hepatic enzyme markers (alanine aminotransferase, ALT, 
and aspartate aminotransferase, AST) and malondialdehyde and increased the activity of 
superoxide dismutase in liver. Histopathology of the liver tissues showed that PDG and  
G-M1 attenuated the hepatocellular necrosis and led to reduction of inflammatory cell 
infiltration. Therefore, the results of this study show that PDG and G-M1 can be proposed 
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to protect the liver against CCl4-induced oxidative injury in mice, and the hepatoprotective 
effect might be attributed to amelioration of oxidative stress. 
Keywords: ginsenoside M1; protopanaxadiol-type ginsenoside; hepatoprotective effect 
 
1. Introduction 
The liver plays a key role in the metabolism, detoxification, and secretionary functions of the body. 
Hepatic injury is a fundamental pathological process in most chronic hepatic diseases and long-standing 
hepatic injury leads to the progressive liver injury, fibrosis, and finally cirrhosis [1]. As it is well 
known, a wide variety of viruses, drugs and toxic chemicals can cause liver injury by means of their 
direct toxicity and/or endogenous toxic metabolic products [2-4]. Carbon tetrachloride (CCl4) is a 
chemical hepatotoxin, which is considered the “gold standard” model of hepatic injury that has the 
advantage of mimicking that caused by different etiologies in humans [5,6]. Extensive research over 
the past decades indicates that some herbal extracts and their chemical constituents can significantly 
inhibit these aforementioned pathologic processes and provide protection against acute and chronic 
liver damage [7-9]. 
Ginseng, the root of Panax ginseng C. A. Meyer, is one of the most famous herbal medicines  
in China, Japan, Korea and other Asian countries [10]. Generally, the pharmacological properties   
of ginseng are attributed to its components the ginsenosides, which can be classified into 
protopanaxadiol-type ginsenosides (PDG, e.g., ginsenosides Rb1, Rb2, Rc, Rd, Rg3, Rh2) and 
protopanaxatriol-type ginsenosides (PTG, e.g., ginsenosides Re, Rg1) based on their sapogenins [11]. 
It is well known that PDG are metabolized by intestinal bacteria after oral administration to their final 
derivative 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (ginsenoside M1, in Figure 1) [12,13]. 
Recently, G-M1 has attracted increasing attention in view of its various biological activities, including 
anti-cancer [14,15], anti-inflammation [16] and anti-diabetes effects[17,18]. 
Figure 1. Proposed bioconversion pathway of PDG to G-M1. 
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In the past several years, various transformation methods, including mild acid hydrolysis [19] and 
microbial conversion [20,21], were used to convert the main ginsenosides to G-M1. However, these 
transformation methods were time-consuming, and resulted in low selectivity and low conversion rates. 
As an alternative of the above preparation methods, enzymatic preparation (EP) has been proposed as 
the most promising for the preparation of active constituents via the selective hydrolysis of the sugar 
moieties, owing to its high specificity, yield and productivity. Recently, snailase (a complex of cellulase, 
hemicellulase, pectinase and β-glucuronidase), extracted from the digestive tract of snails [22], has 
received increasing attention due to its strong hydrolytic abilities [23]. During our research aiming to 
convert main protopanaxadiol-type ginsenosides to ginsenoside M1, we employed snailase to transform 
PDG to GM1 with great success after its comparing hydrolysis ability with other conventional 
chemical enzymes (Figure 1 shows the proposed bioconversion pathway of PDG to G-M1). 
Furthermore, though the hepatoprotective effects of ginsenosides Rb1 and G-M1 in tert-butyl 
hydroperoxide-induced acute hepatotoxicity have been reported, little attention has been focused on 
comparison of PDG and G-M1 for treating chronic liver injury. Park et al. have reported that G-M1 
induces apoptosis in T-HSC/Cl-6 cells via caspase-3 activation [24]. To accomplish this goal, we 
transformed PDG by snailase to G-M1, and a classic CCl4-induced chronic liver injury model was 
chosen to study the liver protective effects of PDG and G-M1 in mice. This should be helpful for 
understanding the effect relationship between PDG and G-M1, providing a scientific basis for their 
application as a dietary supplement or drug for the treatment of hepatic injury. 
2. Results and Discussion 
2.1. Biotransformation of PDG to G-M1 
PDG was isolated from ginseng roots by the previously reported method [25]. PDG is mainly 
composed of ginsenosides Rb1, Rb2, Rc, and Rd with contents of 221 mg/g, 198 mg/g, 178 mg/g and 
55 mg/g, respectively. The hydrolyzing ability to convert PDG to CK of several glycolytic enzymes 
based on the glycosidic moiety, snailase, β-glucanase, cellulase and amylase, were evaluated. Although 
the above enzymes gave the same hydrolysis pattern and similar ability, complete hydrolysis to PDG 
in 24 h was only achieved by snailase. Therefore snailase was used to convert PDG to G-M1 under 
optimized conditions. In brief, the snailase was incubated with PDG in a pH 4.5 sodium acetate buffer 
with agitation at a temperature of 50 °C for a reaction time of 24 h. The mixtures were subsequently 
placed in a water bath at 90 °C to finish the enzymatic reaction. The reaction mixtures were 
individually evaporated, dissolved in methanol, and loaded onto a silica gel column (80 cm × 3 cm, 
I.D.; solvent, CHCl3-MeOH = 20:1–15:1) to give G-M1. Figure 2 shows the chromatograms of PDG 
before and after enzymatic preparation. Molecules 2011, 16 10096 
 
 
Figure 2. HPLC analysis of the bioconversion of protopanaxadiol-type ginsenosides to  
G-M1. Incubation time: A, 0 h, B, 24 h. 
 
2.2. Identification of G-M1 by ESI-MS 
Mass spectrometry (MS), especially MS with electrospray ionization (ESI-MS), is a valuable 
analytical tool in term of providing information on the molecular weights of polar and thermally labile 
compounds. In the present study, the structure of G-M1 was confirmed by ESI/MS. As shown in 
Figure 3, a high abundance of [M+Na]
+ (645.44) is observed in the positive mode. The results showed 
that the molecular weight of G-M1 was 622. 
2.3. Effects of PDG and G-M1 on Body and Organ Weights 
As Table 1 shows, body weights of the experimental animals were not affected by the administration 
of either CCl4, G-M1 and PDG. However, a significant elevation of relative liver and spleen weight 
was seen at the end of the experimental procedure, indicating that CCl4 induced hypertrophy of   
these tissues. By contrast, G-M1 and PDG groups significantly reduced the elevated weight of liver  
(P < 0.05), suggesting their possible protective effects against liver injury after CCl4 induction.  Molecules 2011, 16 10097 
 
 
Figure 3. ESI/MS spectra of G-M1. Total ion chromatograms from 100 to 800 m/z in ESI 
positive mode. 
 
Table 1. Effects of PDG and G-M1 on body weight and relative organ weight in   
CCl4-intoxicated mice. Mean ± S.D. 
Group  Body weight (g) 
Relative weight (g/g body weight, %) 
Heart Liver Spleen 
Normal control  38.26 ± 2.15  0.51 ± 0.05  5.25 ± 0.31  0.42 ± 0.03 
CCl4 control  37.25 ± 3.56  0.48 ± 0.06  6.98 ± 0.22 #  0.53 ± 0.09 # 
G-M1 + CCl4  39.15 ± 3.33  0.47 ± 0.08  5.78 ± 0.12 *  0.44 ± 0.07 
PDG + CCl4  40.05 ± 4.15  0.50 ± 0.04  6.23 ± 0.52 *  0.47 ± 0.11 
* Significance P < 0.05, compared with CCl4 control; # Significance P < 0.05, compared with 
normal control group. 
2.4. Effect of PDG and G-M1 on the Serum ALT and AST Levels 
When the liver is injured by CCl4, membrane permeability of the liver parenchyma cells   
intensifies, and the activities of ALT and AST in serum increase sharply as a consequence. Serum  
amino-transferase activities have long been considered as sensitive indicators of hepatic injury [5,7]. 
As shown in Figure 4, the serum levels of the hepatic enzymes AST and ALT were significantly 
elevated (P < 0.05) in the CCl4-treated mice. Compared with CCl4-treated mice (model group), 
treatment with PDG and G-M1 significantly prevented the elevation of these marker enzymes   
(P < 0.05). These results suggest the possibility that PDG and G-M1 can provide protection against 
liver injury after CCl4 induction. 
2.5. Effect of PDG and G-M1 on the Level of SOD and MDA in Liver Homogenate 
SOD is an effective defense enzyme that catalyses the dismutation of superoxide anions into 
hydrogen peroxide (H2O2). The activity of antioxidant enzyme SOD in liver homogenates was 
significantly decreased (P < 0.05) in liver injury model groups when compared to normal control. PDG 
and G-M1 exerted a beneficial effect on antioxidant enzyme since the SOD activity was found to be 
significantly increased in drug treated groups (P < 0.05). Molecules 2011, 16 10098 
 
 
Figure 4. Effect of PDG and G-M1 on serum ALT and AST levels in CCl4-induced liver 
injury in mice. PDG and G-M1 were administrated for a period of 4 weeks at dose of  
300 mg/kg and 30 mg/kg, respectively. Each value is mean ± S.D. for 12 mice in each 
group. * Significance P < 0.05, compared with CCl4 group. # Significance P  < 0.05, 
compared with normal control group. 
 
Malondialdehyde (MDA), a secondary product of lipid peroxidation, is used as an indicator of 
tissue injury involving a series of chain reactions [26,27]. 
A significant increase in MDA level (P < 0.05), an indicator of lipid peroxidation, was found in the 
livers of CCl4-intoxicated mice relative to normal control. Treatment with PDG and G-M1 reversed 
this biochemical parameter significantly towards normal level (P < 0.05, Figure 5). 
Figure 5. Effect of PDG and G-M1 on antioxidant enzyme (SOD) activities (A) and 
hepatic MDA level (B) in CCl4-induced liver injury in mice. PDG and G-M1 were 
administered for a period of 4 weeks at dose of 300 mg/kg and 30 mg/kg, respectively.  
* Significance P < 0.05, compared with CCl4 group. # Significance P < 0.05, compared 
with normal control group. 
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Figure 5. Cont. 
 
2.6. Histopathological Evaluation 
Histopathologic examinations results showing hepatocyte necrosis and inflammatory cell infiltration, 
can be observed in Figure 6. In normal control animals, liver sections showed normal hepatic cells with 
well preserved cytoplasm, prominent nucleus and nucleolus, and central vein (Figure 6A). The liver 
sections of animals treated with CCl4 showed a moderate degree of centrilobular necrosis, and mild 
degree of infiltration of leukocytes (Figure 6B). The histological observations also supported the 
results obtained from the serum enzyme assay. The histological pattern of the livers of the mice treated 
with G-M1 showed a lower degree of leukocyte infiltration and necrosis (Figure 6C). Similar trends 
were also observed in animals treated with PDG (Figure 6D). 
Figure 6. Histopathology of the liver (×100). (A) Normal control; (B) Treated with CCl4; 
(C) Treated with CCl4 + G-M1 (30 mg/kg/day); (D) Treated with CCl4 + PDG   
(300 mg/kg/day). The arrow represents leukocytes with infiltration. 
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3. Experimental 
3.1. Chemicals 
CCl4 was purchased from Sigma Chemicals. The kits for determining AST, ALT, and SOD 
activities as well as MDA content were obtained from the Jiancheng Institute of Biotechnology, 
Nanjing, China. All other chemicals used were of analytical grade and obtained from Beijing Chemical 
Factory, Beijing, China. G-M1 used in this study was isolated and purified from P. ginseng roots in our 
laboratory by a series of chromatography procedures, and its structure was elucidated by comparison 
with spectral data [28]. Its purity was determined to be more than 98.5% by HPLC-UV analysis 
(Agilent 1100 series HPLC instrument). 
3.2. Animals 
Sixty male ICR mice (Experimental Animal Holding of Jilin University), 22 to 25 g, were housed 
individually in cages in a temperature-controlled room with a 12-hour light/dark cycle. After 1 week of 
acclimation, all mice were fasted for 16 h prior to blood/tissue sampling. All experiments were carried 
out in accordance with the guidelines for the Human Treatment of Animals set by the Association of 
Laboratory Animal Sciences and the Good Laboratory Practice Center. 
3.3. Carbon Tetrachloride (CCl4)-Induced Chronic Liver Injury in Mice 
For the chemical liver injury experiments, the animals were randomly divided into four groups each 
consisting of 12 mice. The experimental groups were as follows: Group I served as normal control. 
Groups II-IV were administered orally 5 mL/kg body weight of CCl4 (20% v/v in olive oil) once a 
week for a period of 8 weeks. From week-4 after CCl4 intoxication, Group II served as CCl4 control, 
Groups III-IV were gavaged with PDG and G-M1 daily for a period of 4 weeks at dose of   
300 and 30 mg/kg, respectively. At the end of the experiment, animals were sacrificed by cervical 
dislocation. Blood was collected into non-heparinized capillary tubes and centrifuged (1,500 rpm,  
10 min, 4 °C). Serum was aspirated and stored at −20 °C until assayed as described below. The liver 
was also removed and stored at −80 °C until use. 
3.4. Measurement of Serum ALT and AST 
Liver injury was assessed by estimating serum activities of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) using commercially available test kits. The results were expressed as 
units/litre (U/L). 
3.5. Measurement of SOD and MDA in Liver Homogenate 
Liver samples were homogenized in Tris-HCl buffer (5 mM containing 2 mM of EDTA, pH 7.4) to 
give a 10% (w/v) liver homogenate. The homogenates were then centrifuged at 1,500 rpm for 15 min at 
4 °C and the supernatants were used immediately for the determination of antioxidant status. The SOD 
activity, as well as the MDA level, was determined following the instructions on the kit. In brief, the 
assay for total SOD was based on its ability to inhibit the oxidation of oxyamine by the xanthine-xanthine Molecules 2011, 16 10101 
 
 
oxidase system. The MDA content was determined by the thiobarbituric acid method. All samples 
were assayed in triplicates. The content of MDA was expressed as nanomole, while SOD activity was 
expressed as units per milligram protein (U/mg protein). Protein content of the homogenates was 
determined using a standard commercial kit provided by Beyotime Institute of Biotechnology 
(Shanghai, China). 
3.6. Histopathological Evaluation 
The livers were preserved in 100 mL/L neutral buffered formalin solution and processed routinely 
by embedding in paraffin. Tissue sections (4–5 μm) were stained with hematoxylin and eosin (H&E) 
stain, and observed under light microscope (Leica, Germany). 
3.7. Statistical Analysis 
All data are presented as mean ± standard deviations (S.D.). Statistical significance of the 
differences between groups was assessed by Student’s t-test. Calculations were performed using 
commercial software (GraphPad Software, San Diego, CA, USA). A level of P < 0.05 was taken as 
statistically significant. 
4. Conclusions 
To the best of our knowledge, snailase preparation of G-M1 from PDG has not been reported 
before. The present report highlighted this valuable biotransformation and investigated the process by 
reversed-phase HPLC. We have successfully achieved enzymatic conversion of PDG to G-M1 with  
treatment with snailase for 24 h at 50 °C and pH 4.5. We next evaluated the effects of PDG and G-M1 
on serum ALT, AST and MDA levels, liver tissue antioxidant enzymes and liver histopathological 
changes in CC14 treated mice. The results showed that PDG and G-M1 were effective in the 
prevention of CC14-induced chronic liver injury, and the effects of G-M1 are more significant than that 
of PDG. 
Acknowledgments 
This work was supported by the Jilin Science and Technology Development Plan (20070728-2, 
20096040; 20100914) and Key Project in the National Science and Technology Pillar Program during 
the Twelfth Five-Year Plan Period (2011BAI03B01). 
References and Notes 
1.  Xu, G.S.; Liu, H.N.; Li, J.; Wu, X.L.; Dai, X.M.; Liu, Y.H. Hepatic injury induced by carbon 
dioxide pneumoperitoneum in experimental rats. World J. Gastroenterol. 2009, 15, 3060-3064. 
2.  Bleibel, W.; Kim, S.; D’Silva, K.; Lemmer, E.R. Drug-induced liver injury: Review article.   
Dig. Dis. Sci. 2007, 52, 2463-2471. 
3.  Benjamin, S.B.; Ishak, K.G.; Zimmerman, H.J.; Grushka, A. Phenylbutazone liver injury:   
A clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1981, 1, 255-263. Molecules 2011, 16 10102 
 
 
4.  Au, J.S.; Navarro, V.J.; Rossi, S. Review article: Drug-induced liver injury—Its pathophysiology 
and evolving diagnostic tools. Aliment. Pharmacol. Ther. 2011, 34, 11-20. 
5.  Tipoe, G.L.; Leung, T.M.; Liong, E.C.; Lau, T.Y.; Fung, M.L.; Nanji, A.A. Epigallocatechin-3-
gallate (EGCG) reduces liver inflammation. oxidative stress and fibrosis in carbon tetrachloride 
(CCl4)-induced liver injury in mice. Toxicology 2010, 273, 45-52. 
6.  Yoshikawa, M.; Ninomiya, K.; Shimoda, H.; Nishida, N.; Matsuda, H. Hepatoprotective and 
antioxidative properties of Salacia reticulata: Preventive effects of phenolic constituents on   
CCl4-induced liver injury in mice. Biol. Pharm. Bull. 2002, 25, 72-76. 
7.  Domitrovic, R.; Jakovac, H.; Blagojevic, G. Hepatoprotective activity of berberine is mediated by 
inhibition of TNF-α, COX-2, and iNOS expression in CCl4-intoxicated mice. Toxicology 2011, 
280, 33-43. 
8.  Yang, L.; Wang, C.Z.; Ye, J.Z.; Li, H.T. Hepatoprotective effects of polyprenols from Ginkgo 
biloba L. leaves on CCl4-induced hepatotoxicity in rats. Fitoterapia 2011, 82, 834-840. 
9.  Yurt, B.; Celik, I. Hepatoprotective effect and antioxidant role of sun, sulphited-dried apricot 
(Prunus armeniaca L.) and its kernel against ethanol-induced oxidative stress in rats. Food Chem. 
Toxicol. 2011, 49, 508-513. 
10.  Lin, H.J.; Chen, J.Y.; Lin, C.F.; Kao, S.T.; Cheng, J.C.; Chen, H.L.; Chen, C.M. Hepatoprotective 
effects of Yi Guan Jian, an herbal medicine, in rats with dimethylnitrosamine-induced liver 
fibrosis. J. Ethnopharmacol. 2011, 134, 953-960. 
11.  Qi, L.W.; Wang, C.Z.; Yuan, C.S. Isolation and analysis of ginseng: Advances and challenges. 
Nat. Prod. Rep. 2011, 28, 467-495. 
12.  Wakabayashi, C.; Hasegawa, H.; Murata, J.; Saiki, I. In vivo antimetastatic action of ginseng 
protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral 
administration. Oncol. Res. 1997, 9, 411-417. 
13. Akao, T.; Kida, H.; Kanaoka, M.; Hattori, M.; Kobashi, K. Intestinal bacterial hydrolysis is 
required for the appearance of compound K in rat plasma after oral administration of ginsenoside 
Rb1 from Panax ginseng. J. Pharm. Pharmacol. 1998, 50, 1155-1160. 
14. Lee, I.K.; Kang, K.A.; Lim, C.M.; Kim, K.C.; Kim, H.S.; Kim, D.H.; Kim, B.J.;   
Chang, W.Y.; Choi, J.H.; Hyun, J.W. Compound K, a metabolite of ginseng saponin, induces  
mitochondria-dependent and caspase-dependent apoptosis via the generation of reactive oxygen 
species in human colon cancer cells. Int. J. Mol. Sci. 2010, 11, 4916-4931. 
15.  Kim, D.Y.; Park, M.W.; Yuan, H.D.; Lee, H.J.; Kim, S.H.; Chung, S.H. Compound K induces 
apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J. Agric. Food Chem. 
2009, 57, 10573-10578. 
16.  Joh, E.H.; Lee, I.A.; Jung, I.H.; Kim, D.H. Ginsenoside Rb1 and its metabolite compound K 
inhibit IRAK-1 activation—The key step of inflammation. Biochem. Pharmacol.  2011,  82,  
278-286. 
17.  Yoon, S.H.; Han, E.J.; Sung, J.H.; Chung, S.H. Anti-diabetic effects of compound K versus 
metformin versus compound K-metformin combination therapy in diabetic db/db mice. Biol. 
Pharm. Bull. 2007, 30, 2196-2200. Molecules 2011, 16 10103 
 
 
18. Kim, D.Y.; Yuan, H.D.; Chung, I.K.; Chung, S.H. Compound K, intestinal metabolite of 
ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. 
J. Agric. Food Chem. 2009, 57, 1532-1537. 
19.  Han, B.H.; Park, M.H.; Han, Y.N.; Woo, L.K.; Sankawa, U.; Yahara, S.; Tanaka, O. Degradation 
of ginseng saponins under mild acidic conditions. Planta Med. 1982, 44, 146-149. 
20. Bae, E.A.; Han, M.J.; Choo, M.K.; Park, S.Y.; Kim, D.H. Metabolism of 20(S)- and   
20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological 
activities. Biol. Pharm. Bull. 2002, 25, 58-63. 
21. Wang, L.; Liu, Q.M.; Sung, B.H.; An, D.S.; Lee, H.G.; Kim, A.G.; Kim, S.C.; Lee, S.T.;   
Lm, W.T. Bioconversion of ginsenosides Rb1, Rb2, Rc and Rd by novel β-glucosidase 
hydrolyzing outer 3-O glycoside from Sphingomonas sp. 2F2. Cloning, expression, and enzyme 
characterization. J. Biotechnol. 2011, 156, 125-133. 
22.  You, J.Y.; Peng, C.; Liu, X.; Ji, X.J.; Lu, J.; Tong, Q.; Wei, P.; Cong, L.; Li, Z.; Huang, H. 
Enzymatic hydrolysis and extraction of arachidonic acid rich lipids from Mortierella alpina. 
Bioresour. Technol. 2011, 102, 6088-6094. 
23.  Liu, X.; Cui, Y.; Yang, L.; Yang, S.L. Purification of a ginsenoside-Rb1 hydrolase from Helix 
snailase. Sheng Wu Gong Cheng Xue Bao 2005, 21, 929-933. 
24. Park, E.J.; Zhao, Y.Z.; Kim, J.; Sohn, D.H. A ginsenoside metabolite, 20-O-beta-D-
glucopyranosyl-20(S)-protopanaxadiol, triggers apoptosis in activated rat hepatic stellate cells via 
caspase-3 activation. Planta Med. 2006, 72, 1250-1253.  
25.  Liu, R.; Zhang, J.Z.; Liu, W.C.; Kimura, Y.; Zheng, Y.N. Anti-obesity effects of protopanaxdiol 
types of ginsenosides isolated from the leaves of American ginseng (Panax quinquefolius L.) in 
mice fed with a high-fat diet. Fitoterapia 2010, 81, 1079-1087. 
26. Sigala, F.; Kostopanagiotou, G.; Andreadou, I.; Kavatzas, N.; Felekouras, E.; Sigalas, P.; 
Bastounis, E.; Papalambros, E. Histological and lipid peroxidation changes after administration of 
2-acetylaminofluorene in a rat liver injury model following selective periportal and pericentral 
damage. Toxicology 2004, 196, 155-163. 
27.  Pesh-Imam, M.; Recknagel, R.O. Lipid peroxidation and the concept of antioxygenic potential: 
Vitamin E changes in acute experimental CCl4-BrCCl3- and ethanol-induced liver injury. Toxicol. 
Appl. Pharmacol. 1977, 42, 463-475. 
28.  Quan, L.H.; Cheng, L.Q.; Kim, H.B.; Kim, J.H.; Son, N.R.; Kim, S.Y.; Jin, H.O.; Yang, D.C. 
Bioconversion of Ginsenoside Rd into Compound K by Lactobacillus pentosus DC101 Isolated 
from Kimchi. J. Ginseng Res. 2010, 34, 288-295. 
Sample Availability: Samples of the compounds are available from the authors. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 